Mar 15, 2023, 14:23 PM by

Darling Ingredients’ health brand Rousselot, the global leader1 in collagen-based solutions, announced today that a new study has found that utilization of highly purified gelatin biomaterials for 3D in vitro models can significantly enhance the reliability and reproducibility in these models, creating new possibilities for replacing preclinical animal trials.

Mar 15, 2023, 14:23 PM by

[London, UK] - Clinion, a leading provider of eClinical solutions, has announced the launch of its new AI-powered medical coding solution. This innovative solution is designed to transform the medical coding process for clinical trials, offering a faster, more efficient, and more accurate way to code medical data. Medical coding is a critical component of clinical trials, as it enables researchers to accurately capture and analyze medical data. However, the process of medical coding can be time-consuming, error-prone, and costly, often leading to delays in the clinical trial process. Clinion's new AI Medical Coding is set to revolutionize the clinical trial process by leveraging the power of artificial intelligence to automate medical coding. The solution uses advanced machine learning algorithms to analyze medical data and assign the appropriate medical codes, significantly reducing the time and effort required for manual coding. The solution also provides real-time feedback to clinical trial teams, allowing them to make data-driven decisions more quickly and efficiently. With improved accuracy and speed, Clinion's medical coding solution enables clinical trial teams to deliver high-quality results and insights faster than ever before. "We are thrilled to launch AI Medical Coding, which we believe will transform the clinical trial process," said Manuj Vangipurapu, CEO of Clinion. "By harnessing the power of AI, we can provide clinical trial teams with a faster, more efficient, and more accurate way to code medical data. This will enable our customers to make data-driven decisions more quickly and effectively, ultimately accelerating the drug development process and bringing new treatments to patients faster." Clinion's medical coding solution is the latest addition to its suite of eClinical solutions, which include EDC, RTSM, ePRO, eConsent and CTMS. sWith over 500+ clinical trials successfully conducted using its solutions, Clinion is the go-to partner for companies seeking to streamline their clinical trial process and bring new treatments to market faster. For more information on Clinion's new AI-powered medical coding solution, please visit clinion.com. About Clinion Clinion is a global clinical technology company that offers AI-enabled eClinical solutions consisting of EDC, RTSM, CTMS, eCOA and Document Automation that cover the entire clinical trial lifecycle. Clinion is committed to innovating the future of clinical trials through AI/ML and empowering its partners to manage trials more efficiently at lesser costs. For more information, please visit www.clinion.com.

Mar 15, 2023, 14:22 PM by

Discover the top 5 clinical trial technology trends in 2023. From wearables to AI, Digital Patient engagement tools and techniques that are shaping the future of clinical research

Mar 15, 2023, 14:21 PM by

Orbita, a provider of virtual assistants for healthcare, announced a partnership with Isabel Healthcare that will improve patients’ digital experiences, helping them find the right care for their individual health circumstances.

Mar 15, 2023, 01:00 AM by User Not Found

Bio-IT World | Researchers have found that dyskerin, a protein that provides stability to non-coding small nucleolar RNAs, signals when cutaneous squamous cell carcinomas are preparing to metastasize by migrating to the lymph nodes. Because these cancer cells temporarily stop consuming glucose and instead feed on low-density lipoprotein cholesterol molecules, the new marker may be a promising candidate for treatments involving lipid metabolism inhibitors.

Mar 14, 2023, 09:56 AM by

Confluence of Industries Requires Nimble, Creative, and Cross-functional Expertise that Flexes and Scales For Pure-play and Multi-line Businesses

Mar 14, 2023, 01:00 AM by User Not Found

Bio-IT World | Spatial biology is poised for an explosion in the next few years, said Colin Enderlein, a principle at DeciBio Consulting. Speaking in San Diego at the Molecular and Precision Med Tri-Con, Enderlein shared the results of DeciBio’s recent market report on the space.

Mar 13, 2023, 11:15 AM by

Mar 13, 2023, 11:13 AM by

Mar 13, 2023, 11:11 AM by

Mar 13, 2023, 11:09 AM by

NCC Group – one of the world’s largest and most respected security consultancies with over 35 global offices, 2,000 employees and 14,000 clients – today appointed Doug Klotnia as global capability leader for Managed Services.

Mar 9, 2023, 09:42 AM by

Automata, a leader in open, integrated laboratory automation, announces its expansion into the US. Automata is accelerating scientific and health outcomes by making automation a reality for every lab.

Mar 9, 2023, 09:40 AM by

Today, Thermo Fisher Scientific launched an easy-to-use solution for the analysis of trace elements in environmental, food, and pharmaceutical laboratories. The Thermo Scientific iCAP RQplus ICP-MS Analyzer provides the operational simplicity and stability that laboratories require for ongoing daily analysis of trace elements at low concentrations in a wide range of sample types. The company also announced the Thermo Scientific iSC-65 Autosampler which enhances the productivity of the Thermo Scientific iCAP Qnova Series ICP-MS analyzer and the Thermo Scientific iCAP PRO Series ICP-OES.

Mar 9, 2023, 09:40 AM by

Micropep Technologies appoints Alexandre Frateschi as chief business officer, signaling drive to agTech product commercialization.

Mar 9, 2023, 01:00 AM by User Not Found

Bio-IT World | Kevin Davies and Craig Venter sat down together to celebrate thirty years of the Molecular and Precision Med Tri-Con this week in San Diego on Monday night. Davies—the founding editor of Bio-IT World—gave a guided tour of human genomic research and sequencing since 1991 with Venter offering first person color commentary along the way.

Mar 8, 2023, 10:07 AM by

PRODUCT BRIEF – March 7, 2023 Thermo Fisher Scientific Introduces New Low-Flow HPLC Columns for Proteomic Research Thermo Scientific µPAC Neo HPLC Columns Deliver Improved Separation Performance and Stability for Biologically Complex Samples News: Thermo Fisher Scientific is providing proteomics and biopharmaceutical research laboratories with a new line of low-flow HPLC columns that improve separation performance and stability of biologically complex samples. Overview: Using a unique micro-pillar separation structure, the Thermo Scientific µPAC Neo HPLC Columns enable researchers to investigate proteomics samples in greater detail, from accurate identification of peptides to determination of protein quantities, discovery of disease biomarkers and post-translational modifications. The newest addition to the portfolio is the µPAC Neo low-load trapping column which is ideally suited for the smallest samples sizes in single-cell proteomics separations and features built-in nanoViper connections to the Vanquish Neo UHPLC systems for ease of use and reduced risk of errors. Users of all µPAC Neo columns benefit from excellent column reproducibility, allowing for more reliable data interpretation and confidence in their results. The full µPAC Neo column portfolio offers: • 50 cm µPAC Neo column for routine proteomics • 110 cm µPAC Neo column for comprehensive proteomics • 50 cm µPAC Neo low-load column for single-cell proteomics • µPAC Neo low-load trapping column to support single-cell proteomics separations µPAC Neo columns are manufactured by micromachined etching of silicon wafers, resulting in highly reproducible separation paths. For proteomics researchers, this provides higher column-to-column consistency and longer column lifetimes compared to packed-bed columns, allowing for more robust development and validation of methods and easier study of larger sample batches. Key Applications: Proteomics and biopharmaceutical research Features/Benefits: • Unique column technology that delivers optimal sample coverage and improved protein identification • Extra-high resolution separations of highest complexity samples • Excellent column reproducibility for more reliable data interpretation • Long column lifetimes to reduce the number of column exchanges and increase system uptime Website: To learn more about the new µPAC Neo HPLC Columns, please visit www.thermofisher.com/lowflowHPLCcolumns. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Mar 8, 2023, 10:06 AM by

DCT platform company places in top 6% of private companies; recognized for end-to-end clinical trial execution built on cutting-edge software

Mar 8, 2023, 01:00 AM by User Not Found

Bio-IT World | A research collaboration led by led by Duke-NUS Medical School and National Heart Centre Singapore has set the stage for telomere measurement to one day be added to the list of clinical-grade methods for assessing biological aging. The focus is on rapid and precise measurement of individual telomeres using a technique that employs “telobaits” that latch onto the ends of telomeres in large pools of DNA fragments.

Mar 7, 2023, 09:27 AM by

Mar 7, 2023, 09:26 AM by

A Pharmacogenomic Breakthrough Translating Personalized Gene Expression to Therapies